Brokerages Set Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) PT at $11.26
Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) have been assigned an average recommendation of “Hold” from the seven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $11.26.
ANTH has been the topic of a number of recent research reports. Jefferies Group LLC restated a “hold” rating and set a $2.25 price objective on shares of Anthera Pharmaceuticals in a research note on Monday, May 15th. Zacks Investment Research lowered Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 8th. Finally, ValuEngine lowered Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
Several institutional investors have recently modified their holdings of ANTH. Goldman Sachs Group Inc. increased its position in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares in the last quarter. Sabby Management LLC increased its position in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares in the last quarter. Finally, UBS Group AG increased its position in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares in the last quarter.
Shares of Anthera Pharmaceuticals (ANTH) remained flat at $1.37 during trading on Friday. 44,836 shares of the company’s stock traded hands. The company’s market cap is $13.80 million. The firm’s 50-day moving average is $1.62 and its 200 day moving average is $1.10. Anthera Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $28.40.
Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.47) by $0.56. Equities research analysts expect that Anthera Pharmaceuticals will post ($5.06) earnings per share for the current year.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.